In-vitro and in-vivo evaluation of austocystin D liposomes

Li, Shuo; Hu, Jie; Zhang, Linan; Zhang, Li; Sun, Yongjun; Xie, Yinghua; Wu, Shaomei; Liu, Lei

doi:10.1111/j.2042-7158.2012.01606.x

Cited by 10 publications

(8 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the compound is not commercially available. Austocystin D is an organic heteropentacyclic compound isolated from Aspergillus and Aspergillus ustus and has been identified as a potent cytotoxic agent with in vivo antitumor activity and selectivity for cells expressing the multidrug resistance transporter MDR1, which was a characteristic of ACC as well [ 22 – 24 ]. Selective cytotoxic action of austocystin D arises from its selective activation by cytochrome P450 (CYP) enzymes in specific cancer cell lines, leading to induction of DNA damage in cells and in vitro [ 25 ].…”

Section: Discussionmentioning

confidence: 99%

ASXL1 promotes adrenocortical carcinoma and is associated with chemoresistance to EDP regimen

Wang

Lyu

et al. 2021

Aging

View full text Add to dashboard Cite

Adrenocortical carcinoma (ACC) is a rare but aggressive disease that lacks definitive treatment. We aim to evaluate role of ASXL1 in ACC and exploit its therapeutic merits therein. We performed in silico reproduction of datasets of the Cancer Genome Atlas (TCGA), GDSC (Genomics of Drug Sensitivity in Cancer) and Human Protein Atlas using platforms of cBioPortal, UALCAN, NET-GE, GSEA and GEPIA. Validation in ACC was performed in tissue, in vitro and in vivo using the NCI-H295R and SW-13 cells. ASXL1 was gained in over 50% of ACC cases with its mRNA overexpressed in DNA gained cases. ASXL1 overexpression was associated with recurrence and worsened prognosis in ACC. ASXL1 gain was associated with resistance to etoposide, doxorubicin and cisplatin (EDP). ASXL1 expression was positively correlated with FSCN1 expression. Targeting ASXL1 significantly impaired fitness of ACC cells, which could be in part rescued by FSCN1 overexpression. Targeting FSCN1 however could not rescue resistance to EDP induced by ASXL1 overexpression. Targeting ASXL1 sensitized ACC cells to EDP regimen but constitutive ASXL3 overexpression in SW-13 cells could induce resistance upon prolonged treatment. Functional gain of ASXL1 was common in ACC and exerted pro-tumorigenic and chemoresistance role. Targeting ASXL1 hold promise to ACC treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

ASXL1 promotes adrenocortical carcinoma and is associated with chemoresistance to EDP regimen

Wang

Lyu

et al. 2021

Aging

View full text Add to dashboard Cite

show abstract

“…Isotype antibodies were purchased from BD Biosciences (San Jose, CA, USA). Human colon carcinoma Caco-2 cell line (passages [20][21][22][23][24][25][26][27][28][29][30] and human Burkitt's lymphoma Raji B line (passages [30][31][32][33][34][35][36][37][38][39][40] were purchased from American Type Culture Collection (ATCC) (Manassas, VA, USA) and used within the passage mentioned in the parentheses. EFV drug powder and all other chemicals were obtained from Sigma-Aldrich Co.…”

Section: Materials and Methods Materialsmentioning

confidence: 99%

“…It is reported that the dialysis bag may limit the in vitro drug release. 37 Although there is a drug release delay and about 15% of drug remained in the dialysis bag from this in vitro method, this dose decrease will not affect the administrated drug for the future in vitro and in vivo application. Even considering this delay impact from dialysis bag, the dissolution profile for our Pluronic nanodrug formulation is still adequate for sustained drug release requirement.…”

mentioning

confidence: 97%

Preparation and characterization of anti-HIV nanodrug targeted to microfold cell of gut-associated lymphoid tissue

Roy

Ding

Pilakka-Kanthikeel

et al. 2015

IJN

View full text Add to dashboard Cite

The human immunodeficiency virus 1 (HIV-1) still remains one of the leading life-threatening diseases in the world. The introduction of highly active antiretroviral therapy has significantly reduced disease morbidity and mortality. However, most of the drugs have variable penetrance into viral reservoir sites, including gut-associated lymphoid tissue (GALT). Being the largest lymphoid organ, GALT plays a key role in early HIV infection and host–pathogen interaction. Many different treatment options have been proposed to eradicate the virus from GALT. However, it becomes difficult to deliver traditional drugs to the GALT because of its complex physiology. In this regard, we developed a polymer-based Pluronic nanocarrier containing anti-HIV drug called efavirenz (EFV) targeting Microfold cells (M-cells) in the GALT. M-cells are specialized epithelial cells that are predominantly present in the GALT. In this work, we have exploited this paracellular transport property of M-cells for targeted delivery of Pluronic nanocarrier tagged EFV, bioconjugated with anti-M-cell-specific antibodies to the GALT (nanodrug). Preliminary characterization showed that the nanodrug (EFV-F12-COOH) is of 140 nm size with 0.3 polydispersion index, and the zeta potential of the particles was −19.38±2.2 mV. Further, drug dissolution study has shown a significantly improved sustained release over free drugs. Binding potential of nanodrug with M-cell was also confirmed with fluorescence microscopy and in vitro uptake and release studies. The anti-HIV activity of the nanodrug was also significantly higher compared to that of free drug. This novel formulation was able to show sustained release of EFV and inhibit the HIV-1 infection in the GALT compared to the free drug. The present study has potential for our in vivo targeted nanodrug delivery system by combining traditional enteric-coated capsule technique via oral administration.

show abstract

“…The OD was monitored using ELISA reader at 570 nm. Cell viability percentage and IC 50 (50% inhibitory concentration of cell growth in comparison to untreated control cells as negative control), 22,23 were determined. All tests were done in triplicate.…”

Section: Cytotoxicity Assessmentmentioning

confidence: 99%

“…It is due to the suitable size of liposomal formulations, type, size of cells, incubation time, and a high tendency between liposome and the cell. 22,[39][40][41][42]…”

Section: Cellular Uptake Studiesmentioning

confidence: 99%

Development and Characterization of Nanoliposomal Hydroxyurea Against BT-474 Breast Cancer Cells

et al. 2019

View full text Add to dashboard Cite

Purpose: Hydroxyurea (HU) is a well-known chemotherapy drug with several side effects which limit its clinical application. This study was conducted to improve its therapeutic efficiency against breast cancer using liposomes as FDA-approved drug carriers. Methods: PEGylated nanoliposomes-containing HU (NL-HU) were made via a thin-film hydration method, and assessed in terms of zeta potential, size, morphology, release, stability, cellular uptake, and cytotoxicity. The particle size and zeta potential of NL-HU were specified by zeta-sizer. The drug release from liposomes was assessed by dialysis diffusion method. Cellular uptake was evaluated by flow cytometry. The cytotoxicity was designated by methyl thiazolyl diphenyl-tetrazolium bromide (MTT) test. Results: The size and zeta value of NL-HU were gotten as 85 nm and -27 mV, respectively. NL-HU were spherical.NL-HU vesicles were detected to be stable for two months. The slow drug release and Weibull kinetic model were obtained. Liposomes considerably enhanced the uptake of HU into BT-474 human breast cancer cells. The cytotoxicity of NL-HU on BT-474 cells was found to be significantly more than that of free HU. Conclusion: The results confirmed these PEGylated nanoliposomes containing drug are potentially suitable against in vitro model of breast cancer.

show abstract

In-vitro and in-vivo evaluation of austocystin D liposomes

Abstract: This study indicates that AD-Ls are a potential carrier of AD for the treatment of tumours in the liver, increasing the cure efficiency and decreasing the side effects on other tissues.

Cited by 10 publications

References 26 publications

ASXL1 promotes adrenocortical carcinoma and is associated with chemoresistance to EDP regimen

ASXL1 promotes adrenocortical carcinoma and is associated with chemoresistance to EDP regimen

Preparation and characterization of anti-HIV nanodrug targeted to microfold cell of gut-associated lymphoid tissue

Development and Characterization of Nanoliposomal Hydroxyurea Against BT-474 Breast Cancer Cells

Contact Info

Product

Resources

About